# Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis

> **NCT01059344** · PHASE3 · COMPLETED · sponsor: **Tillotts Pharma AG** · enrollment: 281 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Mesalamin

## Key facts

- **NCT ID:** NCT01059344
- **Lead sponsor:** Tillotts Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-08
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059344, "Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01059344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*